Company Overview - Air Lease Corporation (ALC) operates as a significant aircraft leasing platform with over $50 billion in assets[9] - The company maintains a young fleet with an average age of 4.7 years[10] - ALC boasts a high aircraft utilization rate of 100% in 1Q 2024[10] - The company has $6.5 billion in liquidity, comprising $0.6 billion in unrestricted cash and $6.0 billion available under a revolving credit facility as of March 31, 2024[10, 11] Financial Performance - ALC has $30.6 billion in committed rentals, including $16.6 billion from the existing fleet and $14.0 billion from aircraft to be delivered from the remainder of 2024 through 2028[10, 11] - As of March 31, 2024, ALC's total assets amounted to $30.9 billion[10, 11] - The adjusted pre-tax return on common equity is 11.6%[10] - The company's debt-to-equity ratio is 2.69x, with secured debt accounting for 1.0% of total assets as of March 31, 2024[86] Fleet and Order Book - ALC's fleet includes 472 owned aircraft and 73 managed aircraft[49] - The net book value of flight equipment subject to operating lease is $26.5 billion[49] - The company has commitments to purchase 320 aircraft from Boeing and Airbus for delivery through 2029, with an estimated aggregate commitment of $20.9 billion[11] - ALC is 100% placed through 2025 on long-term leases[10, 60]

Company Overview - Air Lease Corporation (ALC) operates as a \$50+ billion aircraft leasing platform [9, 11] - The company's fleet has a young average age of 46 years [10] - ALC boasts a high aircraft utilization rate of 1000% in 3Q 2024 [10] Financial Highlights - ALC has \$32 billion in total assets [10] - The company has \$30 billion in committed rentals [10] - ALC maintains a strong liquidity position of \$75 billion [10] - The adjusted pre-tax return on common equity is 101% [10] Order Book and Deliveries - ALC has commitments to purchase 287 aircraft from Boeing and Airbus for delivery through 2029, with an estimated aggregate commitment of \$182 billion [11, 63, 68] - The company has placed 95% of its committed orderbook on long-term leases for aircraft delivering through the end of 2026 [11, 63, 68] - ALC expects to deliver 130 aircraft through 2026, of which 100% are placed [11, 63, 68]

The Company routinely posts information that may be important to investors in the "Investors" section of the Company's website at www.airleasecorp.com. Investors and potential investors are encouraged to consult the Company's website regularly for important information about the Company. The information contained on, or that may be accessed through, the Company's website is not incorporated by reference into, and is not a part of, this presentation. In addition to financial results prepared in accordance wi ...

June 9, 2025 1 NASDAQ: DARE www.darebioscience.com ©2025 Daré Bioscience | All rights reserved 1 TRANSFORMING WOMEN'S HEALTH We founded Daré with the sole focus of putting women's health first – to boldly address existing gaps and give women the treatment options they want and deserve In Italian, it means "TO GIVE" DARE: In English, it means "TO BE BOLD" 2 2 Forward-Looking Statements; Disclaimers This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer ...

XmAb® Antibody Therapeutics Antibodies by Design™: May 2019 Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's development plans and timelines; potential regulatory actions; expected use of cash resources; the timing and results of clinical trial ...

Investor and Analyst Day June 3, 2025 1 Welcome and Agenda Allison Wey SVP, Investor Relations and Corporate Communications Copyright © 2021 -2025 Xeris Pharmaceuticals, Inc. All rights reserved . 2 Important Disclosures Forward-LookingStatements and Other Information Any statements in presentation other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma H ...

Investment highlights. Leading Freelancing Platform to Drive the Future of Work May 2025 Disclaimer You must read the following before continuing. The following applies to this presentation, the oral presentation of this information in this document by Fiverr International Ltd. ("Fiverr" or the "Company") or any person on behalf of the Company, and any question-and-answer session that follows any oral presentation. In accessing this presentation, you agree to be bound by the following terms and conditions. ...

Global Leaders in IgM Antibodies JP Morgan Healthcare Conference January 12, 2022 Forward-looking statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of IGM Biosciences, Inc. (the "Company," "we" or "our") with respect to the Company's future financial condition, results of operations, business strategy, expectations, milestones and plans. All statements other than statements of historica ...

2025 COMPANY OVERVIEW The following factors, in addition to those discussed in our press releases and filings with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from our current expectations expressed in forward-looking statements: 3 ▪ a significant decline in customer demand for our transportation assets or services, including as a result of: ▪ prolonged inflation or deflation ▪ high interest rates ▪ weak macroeconomic conditions and world trade policies ▪ wea ...

Corporate Presentation August 6, 2024 1 Forward Looking Statements Please visit www.TAVALISSE.com for Full Prescribing Information. Please visit www.REZLIDHIA.com for Full Prescribing Information, including Boxed WARNING. Please visit www.GAVRETO.com for Full Prescribing Information. 2 Growing Our Hematology and Oncology Business Commercial Execution Development & Expansion Development Programs1 In-Licensing and Product Acquisition • Identify new late-stage assets which leverage current capabilities and cap ...